Keros Therapeutics Inc. (KROS)
NASDAQ: KROS
· Real-Time Price · USD
14.58
0.14 (0.97%)
At close: May 01, 2025, 3:59 PM
14.57
-0.07%
After-hours: May 01, 2025, 07:11 PM EDT
0.97% (1D)
| Bid | 13.05 |
| Market Cap | 592.11M |
| Revenue (ttm) | 3.55M |
| Net Income (ttm) | -187.35M |
| EPS (ttm) | -5 |
| PE Ratio (ttm) | -2.92 |
| Forward PE | -3.38 |
| Analyst | Hold |
| Ask | 14.9 |
| Volume | 510,741 |
| Avg. Volume (20D) | 1,113,616 |
| Open | 14.39 |
| Previous Close | 14.44 |
| Day's Range | 14.18 - 14.65 |
| 52-Week Range | 9.12 - 72.37 |
| Beta | 1.39 |
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in pat...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 8, 2020
Employees 169
Stock Exchange NASDAQ
Ticker Symbol KROS
Website https://www.kerostx.com
Analyst Forecast
According to 13 analyst ratings, the average rating for KROS stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 71.47% from the latest price.
Stock ForecastsNext Earnings Release
Keros Therapeutics Inc. is scheduled to release its earnings on May 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+18.49%
Keros Therapeutics shares are trading higher. The ...
Unlock content with
Pro Subscription
3 months ago
-16.51%
Keros Therapeutics shares are trading lower after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.
